4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - 4D Molecular Therapeutics is focused on developing innovative solutions for retinal care, aiming to eliminate the need for lifelong injections [2][3] - The company is led by Dr. David Kirn, who serves as the Co-Founder and CEO [2] Product Pipeline - The lead product candidate of 4D Molecular Therapeutics is 4D-150, which targets neovascular diseases of the retina [3] - The presentation will outline the company's recent accomplishments and future potential, particularly regarding 4D-150 [2][3] Market Potential - The presentation will discuss the size and growth of the markets related to retinal care, highlighting significant unmet medical needs [3] - There is an emphasis on the importance of addressing these unmet needs to capture market opportunities [3] Development Strategy - The company will outline its strategy for Phase III trials and commercialization, focusing on derisking the approval process and enhancing commercial potential [3]